Search

Memorial Sloan Kettering Cancer Center (MSK) today announced it has received a new grant from the National Cancer institute (NCI), part of the National Institutes of Health, under the umbrella of the Cancer Moonshot, to create the MATCHES (Making Telehealth Delivery of Cancer Care at Home Effective and Safe) Telehealth Research Center at MSK, a first of its kind.

… Thursday, August 18, 2022 Memorial Sloan Kettering Cancer Center (MSK) today announced it has received a new grant from the National Cancer institute (NCI), part of the National Institutes of Health, under the umbrella of the Cancer Moonshot, to create the MATCHES (Making Telehealth Delivery of Cancer

A new project called the BRCA Exchange is sharing data about BRCA mutations and what they actually mean for cancer risk.

… Monday, February 11, 2019 Summary Clinical genetics experts from MSK and other institutions have launched the BRCA Exchange. This online database shares information about individual BRCA mutations and how they might increase cancer risk. Many people have heard that mutations in the genes BRCA1 and BRCA2

A protein detected in the urine of children with Wilms’ tumor led to the development of a test to improve diagnosis and treatment.

… Thursday, August 8, 2019 Summary Wilms’ tumor is the most common kidney cancer in children. Researchers have detected a protein called prohibitin in the urine of people with aggressive Wilms’ tumor. This discovery could help doctors identify people at risk for the cancer returning after treatment and

A groundbreaking international study has found that imlunestrant plus abemaciclib significantly improved progression-free survival (PFS) versus imlunestrant monotherapy in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer, regardless of prior CDK 4/6 inhibitors, ESR1 or PI3K pathway mutations.

… Wednesday, December 11, 2024 A groundbreaking international study has found that imlunestrant plus abemaciclib significantly improved progression-free survival (PFS) versus imlunestrant monotherapy in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative (ER

The largest, most comprehensive study of its kind from Memorial Sloan Kettering Cancer Center finds that the biology of colorectal cancer in people under 50 is very similar to the disease in older people and more aggressive treatment of younger patients may not be warranted.

… Wednesday, August 18, 2021 Could colorectal cancer in people under 50 years old be biologically different and more aggressive than colorectal cancer in older people? That’s what some researchers have proposed as people in their 20s, 30s, and 40s face a disturbing rise in colorectal cancer — people who

El estudio más grande y más completo de su tipo, realizado por el Memorial Sloan Kettering Cancer Center, concluye que la biología del cáncer colorrectal en personas menores de 50 años es muy similar a la de los pacientes de mayor edad, y que podría no estar justificado aplicar tratamientos más agresivos en los pacientes más jóvenes.

… Wednesday, August 18, 2021 ¿Podría el cáncer colorrectal en las personas menores de 50 años ser biológicamente diferente y más agresivo que el cáncer colorrectal en las personas mayores? Eso es lo que algunos investigadores han propuesto, ya que las personas de 20, 30 y 40 años se enfrentan a un aumento

Memorial Sloan Kettering Cancer Center (MSK) and Lehigh Valley Health Network (LVHN) announced today the beginning of a unique and forward-thinking collaboration aimed at improving patient access to the latest and most effective cancer treatment advances and highest-caliber cancer care.

… Tuesday, August 4, 2015 Memorial Sloan Kettering Cancer Center (MSK) and Lehigh Valley Health Network (LVHN) announced today the beginning of a unique and forward-thinking collaboration aimed at improving patient access to the latest and most effective cancer treatment advances and highest-caliber cancer

Dana Pe’er, PhD, computational biologist and lab head at Memorial Sloan Kettering Cancer Center’s (MSK) Sloan Kettering Institute (SKI), is one of 33 biomedical researchers named a Howard Hughes Medical Institute (HHMI) investigator today.

… Thursday, September 23, 2021 Dana Pe’er, PhD , computational biologist and lab head at Memorial Sloan Kettering Cancer Center’s (MSK) Sloan Kettering Institute (SKI), is one of 33 biomedical researchers named a Howard Hughes Medical Institute (HHMI) investigator today. The elite group of scientists,

An enzyme that contributes to plaque formation in the brain also serves as a first line of defense against bacteria and viruses, suggesting a link between the two.

… Wednesday, September 2, 2020 Summary Scientists at the Sloan Kettering Institute have discovered a direct link between the immune response to viruses and bacteria and the development of plaques in the brain that characterize Alzheimer’s disease. Alzheimer’s disease is a neurodegenerative condition that

Memorial Sloan Kettering’s vision is nothing less than to revolutionize the treatment of cancer. Learn about some of the ways we’re doing it.

… Friday, July 11, 2014 Summary Memorial Sloan Kettering’s vision is nothing less than to revolutionize the treatment of cancer. Learn about some of the ways we’re doing it. The word “transformation” perfectly characterizes and captures the past year at Memorial Sloan Kettering. Indeed, it’s the word we